During the recent session, Moderna Inc (NASDAQ:MRNA)’s traded shares were 1.16 million, with the beta value of the company hitting 1.60. At the last check today, the stock’s price was $41.45, reflecting an intraday loss of -1.31% or -$0.55. The 52-week high for the MRNA share is $170.47, that puts it down -311.27 from that peak though still a striking 13.63% gain since the share price plummeted to a 52-week low of $35.80. The company’s market capitalization is $15.95B, and the average intraday trading volume over the past 10 days was 8.66 million shares, and the average trade volume was 7.60 million shares over the past three months.
Moderna Inc (MRNA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.61. MRNA has a Sell rating from 2 analyst(s) out of 17 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 12 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -2.57.
Moderna Inc (NASDAQ:MRNA) trade information
Moderna Inc (MRNA) registered a -1.31% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.31% in intraday trading to $41.45, hitting a weekly high. The stock’s 5-day price performance is 2.52%, and it has moved by -2.65% in 30 days. Based on these gigs, the overall price performance for the year is -61.83%. The short interest in Moderna Inc (NASDAQ:MRNA) is 39.49 million shares and it means that shorts have 4.37 day(s) to cover.
The consensus price target of analysts on Wall Street is $77.5, which implies an increase of 46.52% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $55 and $238 respectively. As a result, MRNA is trading at a discount of -474.19% off the target high and -32.69% off the low.
Moderna Inc (MRNA) estimates and forecasts
Statistics show that Moderna Inc has outperformed its competitors in share price, compared to the industry in which it operates. Moderna Inc (MRNA) shares have gone down -64.97% during the last six months, with a year-to-date growth rate more than the industry average at 24.57% against 16.80. In the rating firms’ projections, revenue will decrease -51.93% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.05B as predicted by 13 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 140.32M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 2.81B and 167M respectively. In this case, analysts expect current quarter sales to shrink by -62.48% and then drop by -15.97% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -20.02%. While earnings are projected to return 24.34% in 2025.
MRNA Dividends
Moderna Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Moderna Inc (NASDAQ:MRNA)’s Major holders
Moderna Inc insiders own 9.52% of total outstanding shares while institutional holders control 71.55%, with the float percentage being 79.08%. BAILLIE GIFFORD & CO is the largest shareholder of the company, while 1198.0 institutions own stock in it. As of 2024-06-30, the company held over 43.45 million shares (or 11.3741% of all shares), a total value of $5.16 billion in shares.
The next largest institutional holding, with 39.56 million shares, is of VANGUARD GROUP INC’s that is approximately 10.3568% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $4.7 billion.
